Fourteen American vaccines, two of which are in phase III clinical trials, are currently being developed under the aegis of Moncef Slaoui, the chief scientific advisor of Operation Warp Speed.
Since his appointment and on several occasions, the eminent Moroccan-American immunologist has insisted on the importance of depoliticizing the process of developing a vaccine against COVID-19. For Mr. Saloui, an efficacy of 75% to 90% is necessary to gain approval from the FDA, a result he expects for at least two vaccines in early January 2021.
Moncef Saloui estimates that by then the factories under contract will have produced enough vaccine for 30 to 40 million people and will reach enough doses for an additional 80 to 90 million people each month thereafter. “Assuming nothing is wrong, there will be enough doses for the 330 million Americans to be vaccinated by next June or at best by the end of April,” he adds.
In addition, the two US vaccines most advanced in the clinical trial process are those from Moderna and Pfizer-BioNTech. The latter plan to cross the threshold of 30,000 tests in the week.
In addition, during an interview with the American site “Axios”, published Friday, October 16, Mr. Slaoui announced that the Moderna vaccine would reach the end of phase III trials in the next week, highlighting the significant diversity in terms volunteers for testing.
Mr Slaoui also expressed his hope to see Moderna’s vaccine ready by the end of November. According to him, Moderna will apply, within two or three weeks, for an “emergency use license” from the Food and Drug Administration (FDA), after completing the vaccine trials and ensuring its effectiveness.
The immunologist estimated that due to the outcome of the vaccine after the US presidential elections, its politicization, “which greatly disrupted the progress of the vaccination process”, will be limited, adding that “the most important factor that rest is the production of a healthy vaccine ”.
Recall to conclude that the pharmaceutical giant Pfizer declared on its website on Friday that it will not request emergency authorization for its COVID-19 vaccine candidates before at least the third week of November, also putting an end to the efforts of the President Donald Trump to obtain a safe and effective vaccine by November 03.